Neurological side effects linked to GLP-1 receptor agonist drugs reported to the FDA

Among 28,953 neurological adverse event reports associated with glucagon-like peptide-1 receptor agonists, 19 distinct signals were identified.

• Common neurological adverse events include dizziness, tremor, and taste disorder.
• The median time from treatment initiation to onset of neurological adverse events was 32 days.
• Nearly 45.28% of these adverse events occurred within the first 30 days of treatment.
• Different statistical methods confirmed the reliability of the identified signals.
• Findings indicate the necessity for increased clinical awareness regarding these potential adverse events.

Simplified